NCT03539380Available不适用
TRx0237 for the Treatment of Early and Mild-Moderate Alzheimer's Disease: Intermediate-Size Patient Population
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Available
研究概览
简要总结
This is an expanded access program (EAP) for eligible participants. This program is designed to provide continued access to TRx0237 to individual patients with early and mild-moderate Alzheimer's disease who do not qualify for participation in an ongoing clinical trial. Eligible participants must have previously completed participation in a clinical trial of TRx0237 conducted by TauRx or have previously taken TRx0237 in a compassionate use program, among other criteria. Patients will be considered where a physician can demonstrate clinical benefit for a patient not meeting these criteria; in these cases, TauRx will consider participation of the patient on a case-by-case basis.
研究设计
- 研究类型
- Expanded Access
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Early (encompassing Mild Cognitive Impairment) or mild to moderate Alzheimer's disease, as confirmed by a cognitive assessment
- •Clinical benefit of continued access to TRx0237 is expected to outweigh any perceived risk
- •Ability to travel to the named clinic for regularly scheduled visits.
- •The patient and/or his/her legal representative have been informed of the potential risks and obligations and have given written informed consent for continued treatment consistent with local requirements.
- •Not participating in a clinical trial of another investigational drug.
- •Has one (or more) identified adult study partner who either lives with the subject or has sufficient contact to provide assessment of changes in subject behavior and function over time and information on safety and tolerability; is willing to provide written informed consent for his/her own participation; is able to read, understand, and speak the designated language at the study site; agrees to accompany the subject to each study visit
- •A female patient of child-bearing potential must use adequate birth control (as defined by the protocol) for at least 90 days before beginning treatment and agree to continue its use whilst on treatment and for 30 days after the last dose of TRx0237.
排除标准
- •Swallowing difficulties which prevent taking the medication whole as instructed.
- •Unable to comply with this study protocol or has health concerns that may increase risk, in the opinion of the treating physician
- •Enrolled in a previous TRx0237 clinical trial and either did not complete the clinical trial, had a significant treatment-related adverse event that could cause an undue risk, or progressed to severe Alzheimer's disease
- •Use of drugs for which there is a warning or precaution in the labeling about methemoglobinemia at approved doses (e.g., dapsone, local anesthetics such as benzocaine used chronically, primaquine and related antimalarials)
- •Use of clozapine
- •Clinically significant cardiovascular disease
- •Clinically significant respiratory failure
- •History of clinically significant hematological abnormality or hemoglobin value (confirmed upon repeat) below age/sex appropriate laboratory lower limit of normal
- •Creatinine clearance <15 mL/min
- •Clinically significant alanine transaminase (3×the upper limit of normal [ULN]) and/or bilirubin (2×ULN) values
研究者
相似试验
No Longer Available
不适用
Expanded Access to Rovalpituzumab TesirineSmall Cell Lung CancerNCT03503890AbbVie
Temporarily Not Available
不适用
Expanded Access to Telisotuzumab VedotinNon-Small Cell Lung Cancer (NSCLC)NCT04830202AbbVie
Available
不适用
Intermediate-Size Expanded Access Protocol (EAP) for LP352NCT06149663Longboard Pharmaceuticals
No Longer Available
不适用
Early Access Program of Telaprevir With Peginterferon and Ribavirin in Chronic Hepatitis C SubjectsHepatitis CNCT01508286Janssen-Cilag International NV
Approved For Marketing
不适用
Expanded Access Program (EAP) for Participants With Advanced Cancers and Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations Who Have Exhausted All Treatment OptionsAdvanced Cancers and FGFR Genetic AlterationsNCT03825484Janssen Scientific Affairs, LLC